Skip to main content
SpringerLink
Log in

Use of biosimilars reduces treatment costs in RA

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. funded by Hospira, UK

  2. funded by Egis Pharmaceuticals, Hungary

  3. funded by Sandoz International GmbH, Germany

References

  1. McCarthy G, et al. Introduction of an Infliximab Biosimilar (Ct-P13): a Five-Year Budget Impact Analysis for the Treatment of Rheumatoid Arthritis in Ireland. 16th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PMS22, 2 Nov 2013.

  2. Brodszky V, et al. Budget Impact Analysis of Biosimilar Infliximab Treatment for Rheumatoid Arthritis in Six Central European Countries. 16th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PMS21, 2 Nov 2013.

  3. Whitehouse J, et al. The Cost Saving Potential of Utilizing Biosimilar Medicines in Biologic Naive Severe Rheumatoid Arthritis Patients. 16th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PMS104, 2 Nov 2013.

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Use of biosimilars reduces treatment costs in RA. PharmacoEcon Outcomes News 692, 8 (2013). https://doi.org/10.1007/s40274-013-0893-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-013-0893-5

Search

Navigation